Literature DB >> 19222513

Long-term safety of biologics in dermatology.

Xinaida T Lima1, Elizabeth M Seidler, Hermênio C Lima, Alexandra B Kimball.   

Abstract

The use of biologics in dermatology has increased rapidly. Although most are relatively safe when correctly used and monitored, there are known side effects and adverse events that occur. Selection of patients should be done on a case-by-case basis. Severity of disease, comorbidity profile, drug profile, and cost-effectiveness should be all taken into consideration while deciding to start and/or maintain one of these therapies. Dermatologists should be aware of the benefits and limitations of this class of drugs, as well as the appropriate monitoring. The authors propose a concise overview of the safety profiles of some of the biologics currently used in the dermatologic field.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222513     DOI: 10.1111/j.1529-8019.2008.01212.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  3 in total

Review 1.  Cytokine-based therapy in psoriasis.

Authors:  Anupam Mitra; Robyn S Fallen; Hermenio Cavalcante Lima
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 2.  Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.

Authors:  Wolfgang Weger
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Prescription Behaviour and Barriers to Prescription of Biologicals for Treatment of Chronic Inflammatory Skin Diseases in Dermatological Practice in Two German Federal States.

Authors:  Daniela Weiss; Imke Nordhorn; Linda Tizek; Thomas Werfel; Alexander Zink; Tilo Biedermann; Stephan Traidl; Maximilian C Schielein
Journal:  Acta Derm Venereol       Date:  2021-09-28       Impact factor: 3.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.